Healthcare / Drug Manufacturers - Specialty & GenericNSE
$34.25
-0.57 (-1.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-1.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$557M
P/E
20.1x
↓EV/EBITDA
48.9x
↑ROE
3.0%
↑Gross Margin
7.7%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.3%
FCF CAGR
—
FCF margin
-6.1%
FCF / Net income
-3.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $334.0M · net income $5.6M · FCF $-20.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $334.0M | $334.0M | $400.4M | $300.4M | $223.8M |
| Net Income | $5.6M | $5.6M | $7.1M | $5.6M | $7.0M |
| EBITDA | $11.5M | $11.5M | $13.1M | $12.6M | $14.9M |
| EPS | 0.34 | 0.34 | 0.44 | 0.34 | 0.44 |
| Gross Margin | 7.7% | 7.7% | 6.3% | 8.7% | 13.1% |
| Operating Margin | 1.4% | 1.4% | 1.0% | 2.5% | 4.0% |
| Net Margin | 1.7% | 1.7% | 1.8% | 1.9% | 3.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 |
| Cash Flow | |||||
| Free Cash Flow | $-20.2M | $-20.2M | $23.7M | $-1.2M | $-2.9M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 3.9% | 3.2% | 4.1% |
| Valuation | |||||
| P/E | 20.15 | 20.15 | 153.98 | 130.74 | 149.43 |
| EV/EBITDA | 48.94 | 48.94 | 83.00 | 57.61 | 71.95 |
| P/B | 2.99 | 2.99 | 6.06 | 4.18 | 6.35 |
| Growth & Yield | |||||
| Revenue Growth | -16.6% | -16.6% | 33.3% | 34.2% | — |
| EPS Growth | -22.7% | -22.7% | 29.4% | -22.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
107.5%
EPS terminal req.
$3.04
Spread vs growth
-130.3%
5Y implied EPS CAGR
61.0%
EPS terminal req.
$3.68
Spread vs growth
-83.7%
10Y implied EPS CAGR
33.1%
EPS terminal req.
$5.92
Spread vs growth
-55.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.2%
Start / end P/E
105.4x → 100.7x
EPS bridge
0.44 → 0.34
Residual
+1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.